GlassScriptPhysician profile
Georgina Polanco Castillo
NPI 1578844775
$4,398.13
in general payments reported to CMS, 2019-2025
47 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $704 · 2021: $1,201 · 2022: $705 · 2023: $824 · 2024: $493 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $49.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.61 |
| Education | $49.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $391.97 | 2020-2025 | Jardiance, Lyumjev, Mounjaro |
| Amgen INC. | $284.87 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $272.98 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.87 | 2020-2025 | Jardiance, Synjardy |
| Radius Health, INC. | $263.39 | 2020-2023 | Tymlos |
| Abbvie INC. | $211.89 | 2020-2024 | Lupron Depot, Synthroid |
| Astrazeneca Pharmaceuticals LP | $173.08 | 2020-2023 | Farxiga |
| Dexcom, INC. | $145.30 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $139.76 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $131.29 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $126.32 | 2021-2024 | Recorlev |
| Zealand Pharma US, INC. | $105.11 | 2021-2022 | |
| Ucb, INC. | $98.72 | 2019 | |
| Pfizer INC. | $98.50 | 2021-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgina Polanco Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.